Metabolic Disease CROs

Formerly Covance, Labcorp Drug Development provides comprehensive drug development services from early discovery through post-approval. One of the world's largest CROs with extensive nonclinical and clinical capabilities.

Leading global pharmaceutical and medical device open-access capability and technology platform. WuXi AppTec provides services spanning from discovery through manufacturing across small molecules, biologics, and cell/gene therapies.

Japanese CRO subsidiary providing clinical monitoring, data management, and pharmacovigilance services specializing in small-to-mid-size pharma and biotech sponsors across Asia.

Buenos Aires-based full-service Latin American CRO with operations across Argentina, Chile, Uruguay, Brazil, Peru, Mexico, and Colombia, covering Phase I-IV studies.

Contract research and manufacturing organization offering drug discovery, API synthesis, analytical development, and formulation services to global pharma and biotech.

Preclinical ADME and pharmacokinetics CRO in Pennsylvania providing in vitro and in vivo absorption, distribution, metabolism, and excretion studies as part of Pharmaron's global network.

Preclinical ADME and pharmacokinetic service provider now part of Pharmaron. Specializes in in vitro and in vivo DMPK, drug transporter studies, and metabolite identification.

Exton, Pennsylvania-based preclinical CRO providing in vivo PK/PD studies, ADME services, and GLP bioanalytical testing for small-molecule and biologic drug candidates.

San Diego-based preclinical CRO providing in vitro ADME screening, permeability assays, and metabolic stability studies for drug discovery programmes.

Italian preclinical CRO providing GLP safety pharmacology, general and genetic toxicology, DMPK, and bioanalytical services from Nerviano (Milan) facilities.

Specialty bioanalytical and analytical CRO providing method development, validation, and sample analysis services for pharmaceutical and biotech companies pursuing FDA submissions.

Indian CRO providing Phase I BA/BE studies, bioanalytical testing, clinical pharmacology and early-phase research services with USFDA-inspected facilities in Navi Mumbai.

Australian bioanalytical CRO providing GLP-compliant LC-MS/MS and ligand binding assay services for pharmacokinetic, bioequivalence, and immunogenicity studies supporting global regulatory submissions.

GLP-compliant bioanalytical CRO with 25+ years of LC-MS/MS and GC-MS/MS expertise supporting preclinical-to-clinical drug development from purpose-built facilities.

European ADME and DMPK specialist CRO providing in vitro ADME screening, drug-drug interaction studies, and physicochemical profiling from Macclesfield and Watertown facilities.

Integrated drug discovery and development services company now part of Evotec. Provides ADME/DMPK, safety assessment, and pharmaceutical development services.

Verona, Italy-based integrated drug discovery and development centre providing medicinal chemistry, DMPK, safety assessment, and pharmaceutical development under the Evotec umbrella.

Regional full-service CRO headquartered in Riyadh providing clinical trial monitoring and pharmaceutical consultancy across Egypt, Lebanon, Jordan, Gulf States, and Saudi Arabia.

Hyderabad-headquartered integrated CRDMO providing CRO and CDMO solutions for small and large molecules to 450+ global pharma and biotech clients with 3,000+ professionals.

French CRO providing Phase I-III clinical development services with particular expertise in metabolic disease, endocrinology, and cardiovascular trials across Europe.

Chinese CDMO providing pharmaceutical development and manufacturing services from drug discovery to commercialization, known as a long-term supplier to major pharmaceutical companies including Pfizer.

Specialty preclinical CRO offering bioanalytical chemistry, in vitro ADME screening, physicochemical profiling, and metabolite identification for drug discovery programs.

Clinical pharmacology and bioanalytical CRO providing Phase I studies, bioequivalence, and PK/PD studies from a purpose-built 150-bed clinical pharmacology unit in Dilworth, Minnesota.

Italian CRO providing Phase I clinical pharmacology studies including bioequivalence, food-effect, and drug interaction trials from its dedicated Phase I unit in Milan.

Global CRO/CDMO providing integrated drug discovery and development services including medicinal chemistry, ADME/PK, pharmacology, and process chemistry from US and China operations.

Indian biopharmaceutical company providing biosimilar development, contract manufacturing, and clinical research services with GMP manufacturing facilities for biologics and biosimilars.

South Korean CRO specializing in clinical trial management and data services for pharmaceutical companies developing products for both Korean and global regulatory submissions.

South Korea's first CRO founded in 1997, providing comprehensive Phase I-IV clinical development solutions including regulatory affairs, data management, pharmacovigilance and medical translation.

Independent early-phase CRO in the Netherlands specializing in first-in-human and Phase I trials using innovative biomarkers, with a purpose-built 54-bed clinical research unit adjacent to Leiden University Medical Center.

Nanjing-based clinical CRO and Pharmaron subsidiary providing one-stop clinical development services in China including regulatory affairs, clinical operations, pharmacovigilance, and bioanalysis.

Swiss independent Phase I and early-phase clinical CRO in Basel with a dedicated 24-bed clinical pharmacology unit, specializing in first-in-human studies for oncology, cardiovascular, and CNS compounds.

Full-service Australian CRO delivering clinical research services across Australia and New Zealand, supporting sponsors through Phase I-IV development.

Swedish CRO with a 12-bed first-in-human research unit at Uppsala University Hospital, specializing in Phase I and Phase II trials with approximately five FIH studies annually.

China-based global CRO providing full clinical development services from Phase I through IV with strong site networks across China, Korea, and Southeast Asia.

Swiss clinical pharmacology unit specialising in first-in-human Phase I trials, PK/PD studies, and early-phase bioequivalence studies for small molecules and biologics.

Biosimulation and regulatory science company providing model-informed drug development, regulatory science consulting, and software solutions for the pharmaceutical industry.

Shanghai-headquartered CRO/CDMO offering integrated drug discovery chemistry, biology, and biologics development services including ADC and recombinant protein production.

Ahmedabad-founded full-service CRO and one of Asia's largest BA/BE and early-phase Phase I units, offering clinical, bioanalytical and biometric services across 4 countries.

Singapore-founded full-service CRO with operations across 12 Asia-Pacific markets, offering clinical trial management, regulatory affairs and data services.

Taiwan and China-focused CRO providing clinical development, regulatory strategy, and bioanalytical services with expertise in NMPA/TFDA dual-track submissions for sponsors entering Greater China.

Indian CRO providing clinical data management, biostatistics, pharmacovigilance, and medical writing services for global pharmaceutical and biotech companies at competitive costs.

Bangalore-based CRO subsidiary of Biocon offering early-phase clinical trials, bioequivalence studies, bioanalytical testing and Phase II-IV services with expertise in biosimilars.

Croatian full-service CRO providing Phase I-IV clinical trial management across Central and Eastern Europe with expertise in bioequivalence studies.

Novotech's dedicated Phase I research unit in Sydney providing first-in-human, SAD/MAD, food effect, and bioavailability studies with a 30-bed clinical pharmacology facility.

Monterrey-headquartered CRO operating across Mexico, Argentina, Colombia, and Brazil with 20+ years of clinical research experience merging high-efficiency standards with academic scientific rigour.

GLP-compliant preclinical CRO specializing in toxicology, pathology, and ADME studies for pharmaceutical, biotech, and agrochemical clients with full necropsy and histopathology capabilities.

Full-service clinical CRO providing Phase I-IV development support with emphasis on bioanalytical services, clinical pharmacology, and PK/PD modeling from their Salt Lake City operations.

US-based clinical-stage CRO arm specialising in endocrinology and cortisol-modulation therapeutics with expertise in Phase I-III metabolic and CNS clinical trials.

Labcorp Drug Development's Chinese laboratory providing preclinical safety assessment, bioanalytical services, and clinical trial support for NMPA regulatory submissions.

Labcorp Drug Development's Japanese operations providing preclinical safety assessment, bioanalytical services, and clinical trial support for regulatory submissions to PMDA and other Asian regulatory agencies.

Singapore-based global CRO consulting organisation assisting clients from clinical development through commercialisation with a focus on Asia-Pacific market access.

Full-service CRO with a dual-hub strategy across Eastern Europe and the Balkans, offering end-to-end clinical trial services for Phase I-IV studies with competitive patient recruitment timelines.

Translational oncology and metabolic disease CRO providing tumor models (PDX, syngeneic, humanized), oncology pharmacology, and biomarker services for drug discovery.

Indian CRO affiliated with Dabur offering preclinical drug discovery, IND-enabling studies, and non-clinical research services from facilities near Delhi.

Australia's original full-service CRO since 1987, managing clinical research across all phases and most therapeutic areas for pharma, biotech and medical device companies.

South Korean full-service CRO providing clinical development services from Phase I through post-marketing with bioanalytical capabilities and strong ties to Korean academic medical centers.

South Korea's largest clinical CRO and Tigermed subsidiary, delivering full-scope clinical services with 1,200+ successful projects across pharmaceuticals, biotech, and medical devices.

Japanese CRO group providing clinical development, data management, biostatistics, and regulatory affairs services across Japan, China, Korea, and Southeast Asia.

French preclinical CRO based in Lyon evaluating efficacy and safety of new compounds including drugs, biologics, and medical devices across innovative in-vitro and in-vivo models.

Eurofins Discovery division providing high-throughput in-vitro pharmacology screening, compound profiling, ADME assays, and bioanalytical services supporting drug discovery from target identification through lead optimization.

Drug discovery and development company offering a range of discovery and preclinical services including target validation, hit identification, lead optimization, and ADME/PK.

Croatian integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, and preclinical development services, now part of Polish CRO Selvita Group.

Texas-based Phase I clinical research unit specialising in early-phase, first-in-human, and healthy volunteer studies with integrated bioanalytical capabilities.

Clinical trial arm of Frontage Laboratories providing Phase I-III services with integrated bioanalytical capabilities, bridging bioanalytical strength with full clinical execution.

CRO providing integrated drug discovery and development services including ADME/PK, bioanalytical, CMC, and clinical services with operations in the US and China.

Chinese operations of Frontage Laboratories providing bioanalytical services, ADME/PK studies, and analytical chemistry from GLP-compliant laboratories in Shanghai and Suzhou.

Shanghai-based specialised clinical CRO providing full clinical development services in China and APAC with expertise in navigating NMPA regulatory pathways for multinational pharmaceutical companies.

Indian research services company providing medicinal chemistry, computational chemistry, biology, DMPK, and clinical development services for global pharma and biotech companies.

Asia-Pacific focused full-service CRO providing clinical trial management, data management, and biostatistics services with particular expertise in cardiovascular, renal, and diabetes trials.

Academic CRO based at Griffith University on the Gold Coast, conducting clinical trials in metabolic disease, sports medicine, and natural health products under TGA regulatory framework.

Mexico City-based CRO and leading provider of decentralised clinical trial home visit services, patient recruitment, and community research site networks across 22 Latin American countries.

Chinese CRO and CDMO offering integrated preclinical biology, in-vitro pharmacology, and early drug discovery services for domestic and multinational pharma clients.

Chinese pharmaceutical company providing contract research and clinical development services for pharmaceutical companies seeking NMPA approvals in China.

Phase I clinical research unit in New Jersey providing first-in-human, food effect, bioequivalence, and early-phase pharmacokinetic studies for pharmaceutical sponsors.

ICON's dedicated early development division operating clinical pharmacology units in the US and Europe, conducting first-in-human, PK/PD, food effect, and drug interaction studies.

IQVIA's Indian operations providing comprehensive clinical development, regulatory consulting, and healthcare analytics services for pharmaceutical companies across South Asia.

IQVIA's Japanese subsidiary providing clinical operations, real-world data analytics, regulatory strategy and technology solutions with one of the largest clinical operations teams in Japan.

Chinese preclinical CRO providing GLP-compliant safety evaluation, pharmacokinetics, efficacy studies, and drug metabolism studies with comprehensive NHP and rodent capabilities.

Integrated drug discovery and development services company providing medicinal chemistry, ADME/DMPK, pharmacology, and clinical research from India, US, and China operations.

Therapeutically specialized CRO focused on CNS, cardio-metabolic, renal, and rare disease trials, providing end-to-end CRO and SMO services across 39 countries with 220,000+ subjects enrolled.

Kobe-based Japanese CRO and research institute specializing in preclinical safety assessment, pharmacology and drug metabolism studies with GLP-accredited facilities.

Full-service CRO based in Warsaw providing Phase I-IV clinical trial management, regulatory affairs, site management, and biometrics across Central and Eastern Europe.

US-Korea bridge CRO providing early-phase clinical and regulatory services tailored for Korean life science companies entering the US FDA pathway.

Canadian full-service CRO specialising in clinical trials and regulatory support for nutraceutical, cannabis, and natural health product industries.

South Korean CRO providing Phase I-IV clinical development, bioanalytical services, and regulatory consulting with particular expertise in simultaneous MFDS-FDA-EMA regulatory submissions.

Seoul-based full-service Korean CRO with 400 clinical trial experts and experience across 1,600+ studies including 180+ global multi-center trials.

Indian clinical CRO providing Phase I-IV clinical trials, bioanalytical services, and clinical pharmacology studies with dedicated Phase I units and bioanalytical laboratories.

Spanish full-service CRO and site management organization providing clinical trial management, regulatory affairs, and pharmacovigilance services in Spain, Italy, and Portugal.

Phase I-III CRO and integrated research site network specialising in CNS, pain, obesity, and metabolic disease with wholly-owned clinical units in California.

Bangalore-based Indian CRO offering Phase I bioequivalence, bioanalytical and early-phase clinical research services for domestic and international generic pharmaceutical companies.

Japanese digital health and clinical research subsidiary of M3 Inc., leveraging its physician panel of 300,000+ doctors for clinical trial site identification and recruitment in Japan.

One of Europe's largest full-service CROs with a dedicated network of research sites across the UK, conducting global clinical studies from Phase I through Phase IV with particular strength in patient recruitment.

UK-based Phase I-IV site network and CRO operating multiple dedicated clinical research centres across Northern England for healthy volunteer and patient population studies.

Chinese integrated drug discovery and development CRO providing medicinal chemistry, ADME/PK, pharmacology, toxicology, and CMC services from Shanghai operations.

Scientifically-driven, global, full-service clinical CRO providing Phase I-IV clinical development services. Medpace is known for its therapeutic expertise and operational efficiency.

Danish biomarker CRO specializing in neoepitope biomarker technologies for tissue remodeling, conducting clinical trials in rheumatology, musculoskeletal, and metabolic disease with CAP-accredited laboratories.

Greater China operations of Australian CRO Novotech, providing full-service clinical trial management across mainland China, Hong Kong and Taiwan with NMPA submission expertise.

Fully integrated German CRO/CDMO offering drug discovery, non-clinical studies, pharmaceutical analysis, GMP manufacturing, and early-phase clinical trials from facilities in Germany and France.

Germany-based mid-size CRO providing early-phase clinical trials (Phase I/IIa), bioanalysis, DMPK, and translational medicine services from facilities in Neu-Ulm and Berlin.

The first CRO established in Turkey, providing clinical and epidemiological research management to national and international pharmaceutical companies since 1997.

Leading Central and Eastern European full-service CRO operating across 30+ countries with 510+ staff and 1,700+ completed studies, expanded through acquisitions of Crown CRO, SSS International, and MKS Research.

Full-service CRO headquartered in Dubai covering 31 countries across the Middle East and Africa with clinical operations, regulatory affairs, pharmacovigilance, and data management services.

Central European CRO headquartered in Prague providing full-service Phase I-IV clinical trial management across the Czech Republic, Slovakia, Poland, and Hungary.

Bioanalytical CRO providing GLP-compliant LC-MS/MS and ligand binding assay services for pharmacokinetic, bioequivalence, and immunogenicity sample analysis to support clinical trials.

European CRO providing preclinical contract research services including in vivo pharmacology, toxicology, and bioanalytical testing from GLP-certified European facilities.

Parexel's Japanese arm offering full-service clinical development, regulatory consulting and market access services with deep PMDA submission expertise.

Danish CRO focused on Scandinavian and Nordic clinical trial management, site selection, and regulatory submissions for pharma and medical device sponsors.

Canadian full-service CRO providing clinical research services from Phase I through Phase IV with particular expertise in bioequivalence studies and pharmacokinetic trials.

Integrated pharmaceutical R&D service platform offering drug discovery, preclinical, clinical, and commercial manufacturing services to biotech and pharma companies globally.

Greek CDMO specialising in long-acting injectable (LAI) and controlled-release oral solid dosage development and manufacturing for complex generics and NCEs.

Nordic preclinical CRO providing in vivo pharmacology, efficacy, and safety studies with expertise in metabolic disease, inflammation, and fibrosis models using rodent species.

Clinical research site in Phoenix conducting Phase I-IV clinical trials with particular strength in CNS, pain, and metabolic disease studies with rapid enrollment capabilities.

Multi-site clinical research organization conducting Phase I-IV trials with a network of dedicated research sites across the upper Midwest specializing in diverse therapeutic areas.

Bangalore-based Indian CRO specialising in Phase I-IV clinical trials, bioequivalence studies, and regulatory affairs for domestic and international pharmaceutical companies.

One of the world's largest data-focused biometrics CROs, providing biostatistics, statistical programming, clinical data management, and medical writing without conducting clinical operations.

Translational pharmaceutics CRO/CDMO uniquely combining formulation development and clinical pharmacology under one roof, accelerating drug development timelines by running formulation and clinical testing simultaneously.

Oklahoma-based early-phase clinical research site specialising in Phase I healthy volunteer studies, PK/PD trials, and bioequivalence studies.

Full-service CRO providing clinical research, biostatistics, data management, and regulatory services with particular expertise in ophthalmology, CNS, and rare disease.

National clinical research coordinating body in Singapore established by A*STAR and MOH, offering study design, project management, data management, and biostatistics to pharma and academic sponsors.

India's original CRO founded in 1996 providing clinical trial operations, FSP services, data management, medical writing, biostatistics and pharmacovigilance across global programs.

Japan's pioneering CRO founded in 1957 offering non-clinical safety evaluation including NHP studies, clinical Phase I-IV development, and a proprietary nasal drug delivery platform.

Denmark-based GLP preclinical CRO offering safety pharmacology, general toxicology, reproductive toxicology, and ADME studies, known for rodent and non-rodent capabilities including minipig models.

ASX-listed Taiwanese CDMO providing world-class API synthesis, finished dose form manufacturing, and clinical packaging from GMP facilities in the Southern Taiwan Science Park.

Polish integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, computational chemistry, and preclinical services with 1,000+ scientists across Europe.

Chinese CRO and CDMO providing drug discovery chemistry, DMPK, analytical services, and clinical trial manufacturing from Shanghai and Chengdu operations.

Hyderabad-headquartered pharmaceutical CRO with dedicated clinical trials division providing drug discovery, early-phase clinical, and regulatory support with strong CNS expertise.

Ahmedabad-based mid-size CRO providing Phase I-IV clinical trials, bioequivalence studies, and bioanalytical services to Indian and global generic pharma companies.

Syneos Health's Korean operations providing full-service clinical development support for Korean and global pharmaceutical companies conducting trials in South Korea and APAC markets.

Indian integrated research, development, and manufacturing services company serving pharma, biotech, and nutrition companies with discovery chemistry, biology, and manufacturing capabilities.

European laboratory services provider offering central laboratory, bioanalytical, and diagnostic testing services for clinical trials across Phase I-IV with 40+ labs worldwide.

South Korean genomics and CRO company providing next-generation sequencing, genomic analysis, and precision medicine research services alongside clinical biomarker and pharmacogenomics programs.

China's largest independent CRO providing comprehensive clinical development services from preclinical through post-marketing with operations across China, Asia, and globally.

Indian CRO providing Phase I clinical pharmacology, bioanalytical services, and bioequivalence studies from a 230-bed clinical pharmacology unit in Ahmedabad with USFDA and EMA track record.

Netherlands-based CRO providing Phase I clinical pharmacology, bioequivalence, and early-phase clinical trial services as the European arm of India's Veeda Group.

Integrated clinical research site organization operating 20+ dedicated research sites across the US, providing high-quality Phase I-IV clinical trial execution with rapid patient enrollment.

World's leading site management organization with 90+ integrated research sites and 220+ investigators across the US, specializing in general medicine, vaccines, and infectious disease trials.

Hyderabad-based publicly listed contract research and testing organisation offering integrated preclinical, clinical, and cGMP laboratory services for pharmaceutical companies worldwide.

Chinese CRO/CDMO providing integrated drug discovery services including structure-based drug design, medicinal chemistry, ADME/PK studies, and biologics development from Shanghai operations.

Mid-size global CRO providing Phase I-IV clinical development services with expertise in CNS, cardiovascular, and metabolic disease therapeutic areas.

Mid-size full-service global CRO offering integrated bioanalytical lab services alongside Phase I-IV clinical trial management with a focus on CNS, cardiovascular, and rare disease.

Clinical division of WuXi AppTec providing end-to-end Phase I-IV clinical trial services across China and Asia with expertise in NMPA, FDA and EMA regulatory submissions.

WuXi AppTec's pharmaceutical development and manufacturing arm providing API process development, formulation development, analytical services, and GMP manufacturing from China and US facilities.

Japanese preclinical ADME services company providing in vitro metabolism, transporter, and drug interaction studies using human and animal tissue preparations for drug development.

Specialty ADME/PK CRO providing in vitro and in vivo drug metabolism and pharmacokinetic studies. Known for comprehensive ADME characterization using human and animal tissues.

Kansas City-based in vitro ADME and drug metabolism CRO providing hepatocyte-based assays, enzyme induction/inhibition studies, and metabolite identification services.

South Korean pharmaceutical research institute providing preclinical safety assessment, ADME/PK studies, and efficacy testing from GLP-certified facilities in Seoul.

Physician-led Australian CRO offering full-spectrum clinical and non-clinical services with AI-driven operating model across Phase I-III for innovative biotechs.